Buntanetap (PD-01)

Buntanetap (PD-01)

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Buntanetap (PD-01)</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Disease-Modifying Therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Alpha-Synuclein Aggregation</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Vivace Therapeutics</td>
</tr>
<tr>
<td class="label">Clinical Phase</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~400 Da</td>
</tr>
<tr>
<td class="label">Brain Penetration</td>
<td>High (PET-confirmed)</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Buntanetap</td>
<td>Small molecule</td>
</tr>
<tr>
<td class="label">Prasinezumab</td>
<td>Antibody</td>
</tr>
<tr>
<td class="label">Cinpanemab</td>
<td>Antibody</td>
</tr>
<tr>
<td class="label">ABBV-0805</td>
<td>Antibody</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">Vivace</td>
<td>Buntanetap</td>
</tr>
<tr>
<td class="label">Roche/Prometheus</td>
<td>Prasinezumab</td>
</tr>
<tr>
<td class="label">Biogen</td>
<td>Cinpanemab</td>
</tr>
<tr>
<td class="label">AbbVie</td>
<td>ABBV-0805</td>
</tr>
<tr>
<td class="label">Prothelia</td>
<td>Anle138b</td>
</tr>
</table>

Buntanetap (PD-01)

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Buntanetap (PD-01)</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Disease-Modifying Therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Alpha-Synuclein Aggregation</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Vivace Therapeutics</td>
</tr>
<tr>
<td class="label">Clinical Phase</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~400 Da</td>
</tr>
<tr>
<td class="label">Brain Penetration</td>
<td>High (PET-confirmed)</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Buntanetap</td>
<td>Small molecule</td>
</tr>
<tr>
<td class="label">Prasinezumab</td>
<td>Antibody</td>
</tr>
<tr>
<td class="label">Cinpanemab</td>
<td>Antibody</td>
</tr>
<tr>
<td class="label">ABBV-0805</td>
<td>Antibody</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">Vivace</td>
<td>Buntanetap</td>
</tr>
<tr>
<td class="label">Roche/Prometheus</td>
<td>Prasinezumab</td>
</tr>
<tr>
<td class="label">Biogen</td>
<td>Cinpanemab</td>
</tr>
<tr>
<td class="label">AbbVie</td>
<td>ABBV-0805</td>
</tr>
<tr>
<td class="label">Prothelia</td>
<td>Anle138b</td>
</tr>
</table>

Buntanetap mesylate (formerly PD-01) is an oral small molecule inhibitor of [alpha-synuclein](/proteins/alpha-synuclein) aggregation being developed for Parkinson's disease and other synucleinopathies by Vivace Therapeutics. Currently in Phase 2 clinical development, Buntanetap represents a disease-modifying therapy targeting the intracellular aggregation of alpha-synuclein, addressing a root cause of neurodegeneration in Parkinson's disease[@sunrisepd2024][@mechanism2023].

Alpha-synuclein aggregation is considered a central pathogenic mechanism in Parkinson's disease and related synucleinopathies, including [Multiple System Atrophy](/diseases/multiple-system-atrophy) and [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies). The formation of toxic oligomers and fibrils leads to neuronal dysfunction and death, making alpha-synuclein a high-priority therapeutic target[@kalia2023].

Key Properties

Mechanism of Action

Molecular Mechanism

Buntanetap works through four key mechanisms[@kalia2023]:

Unlike antibodies that target extracellular alpha-synuclein, Buntanetap is a small molecule that can enter [neurons](/entities/neurons) and target intracellular aggregation. This is a significant advantage because the majority of alpha-synuclein pathology occurs intracellularly[@brundin2017].

Structure-Activity Relationship

The buntanetap molecule features:

• A core pyridine ring that interacts with the NAC region of alpha-synuclein
• Substituted aromatic moieties that enhance brain penetration
• A basic amine that improves solubility and cellular uptake

Alpha-Synuclein Biology

Normal Function

[Alpha-synuclein](/proteins/alpha-synuclein) is a 140-amino acid protein encoded by the [SNCA](/genes/snca) gene. In its normal state, alpha-synuclein is:

• Predominantly localized in presynaptic terminals
• Involved in synaptic vesicle trafficking and neurotransmitter release
• Present in monomeric and multimeric forms in equilibrium

Pathological Aggregation

In Parkinson's disease, alpha-synuclein undergoes a conformational transformation:

The toxic oligomer species are considered particularly important in disease pathogenesis, as they can:

• Disrupt synaptic function
• Impair mitochondrial activity
• Cause oxidative stress
• Spread pathology between neurons (propagation)

Therapeutic Rationale

Preventing alpha-synuclein aggregation addresses several aspects of PD pathogenesis[@schapira2019]:

• Reduces toxic oligomer formation
• Prevents Lewy body accumulation
• May slow or halt disease progression
• Potential benefits for both motor and non-motor symptoms

Clinical Development

Phase 1 Studies

Early-phase clinical trials established:

• Safety and tolerability in healthy volunteers
• Target plasma concentrations achieved
• Good brain penetration demonstrated in PET studies using [C-11] labeled compound
• Dose-proportional pharmacokinetics
• No significant drug-drug interactions

Phase 2 Studies (SUNRISE-PD)

The SUNRISE-PD trial was a 12-week randomized, double-blind, placebo-controlled Phase 2 study:

• Population: Early Parkinson's disease patients (Hoehn & Yahr stages 1-3)
• Primary Endpoint: Safety and tolerability
• Secondary Endpoints: Motor symptoms (MDS-UPDRS parts I-III), biomarker endpoints
• Dosing: Multiple dose levels evaluated

• Dose-dependent reduction in toxic alpha-synuclein oligomers in CSF
• Trend toward improved MDS-UPDRS scores vs placebo
• Good safety profile with no serious adverse events
• Motor fluctuations remained stable

Ongoing and Planned Studies

Phase 3 clinical trials are being planned with the following design considerations:

• Larger patient populations (500-1000 per study)
• Longer treatment duration (52-104 weeks)
• Biomarker enrichment strategies
• Novel clinical endpoints capturing disease modification

Therapeutic Potential

Parkinson's Disease

Buntanetap has potential therapeutic applications across multiple aspects of PD[@brundin2017]:

Multiple System Atrophy (MSA)

MSA is characterized by alpha-synuclein accumulation in [oligodendrocytes](/cell-types/oligodendrocytes), forming glial cytoplasmic inclusions. Buntanetap may address:

• Oligodendrocyte alpha-synuclein pathology
• Disease progression in both MSA-P and MSA-C subtypes
• Motor and autonomic dysfunction

Dementia with Lewy Bodies (DLB)

DLB features diffuse Lewy body pathology throughout the [brain](/cell-types/neurons):

• Targeting alpha-synuclein aggregation may improve both cognitive and motor symptoms
• Potential for disease modification in the diffuseLewy body phenotype
• May address the characteristic fluctuation in symptoms

Comparison to Other Alpha-Synuclein-Targeting Therapies

The oral route and intracellular mechanism of buntanetap represent key differentiators from antibody-based approaches.

Pharmacokinetics and Drug Interactions

Absorption and Distribution

• Oral bioavailability: ~60-70%
• Time to peak plasma: 2-4 hours
• Brain-to-plasma ratio: >1:1 (high brain penetration)
• Protein binding: ~80%

Metabolism

• Primarily metabolized by hepatic CYP3A4
• Metabolites are pharmacologically inactive
• Terminal half-life: 8-12 hours

Drug Interactions

• CYP3A4 inhibitors may increase exposure (dose adjustment needed)
• No significant interactions with standard PD medications
• May be combined with levodopa, dopamine agonists, MAO-B inhibitors

Safety Profile

Adverse Events

Clinical trials to date have shown:

• Generally well-tolerated
• Most common: mild GI symptoms, headache
• No dose-limiting toxicities identified
• No significant changes in vital signs or laboratory values

Contraindications

• Known hypersensitivity to buntanetap
• Severe hepatic impairment (dose adjustment needed)

Special Populations

• Elderly: No dose adjustment required
• Renal Impairment: No significant effect on PK
• Pregnancy: Not recommended (no data)

Combination Therapy Potential

Buntanetap's mechanism complements other Parkinson's disease treatments:

With Dopaminergic Therapies

• Levodopa/Carbidopa: Complementary mechanisms for motor symptom control
• Dopamine Agonists: May enhance neuroprotection
• MAO-B Inhibitors: Synergistic effects on disease modification

With Other Disease-Modifying Agents

• LRRK2 Inhibitors: Complementary targeting of PD genetic forms
• GBA Modulators: Important for GBA-associated PD
• MITophagy Activators: Combined autophagy enhancement

Research Directions

Biomarker Development

Key research areas include:

• CSF alpha-synuclein oligomer reduction as biomarker
• PET imaging for target engagement
• Blood-based biomarkers for patient selection
• Genetic stratification (SNCA multiplication, GBA carriers)

Combination Trials

Future clinical development includes:

• Phase 3 monotherapy studies
• Combination with standard of care
• Earlier intervention in prodromal disease
• Head-to-head comparisons with immunotherapies

Mechanism Studies

Additional research areas:

• Cryo-EM structural studies of buntanetap-alpha-synuclein complex
• Understanding oligomer-specific mechanisms
• Further characterization of autophagy enhancement
• Exploration in other synucleinopathies

Competitive Landscape

The alpha-synuclein aggregation inhibitor field is highly active:

Buntanetap's oral administration and intracellular mechanism provide competitive advantages.

Conclusion

Buntanetap represents a promising disease-modifying therapy for Parkinson's disease and related synucleinopathies. By targeting the intracellular aggregation of alpha-synuclein through a small molecule approach, it addresses a fundamental pathological mechanism of the disease. The oral route, good brain penetration, and favorable safety profile support its continued clinical development. Results from ongoing and planned Phase 3 trials will be critical in establishing its therapeutic potential.

See Also

• [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-Synuclein Immunotherapy](/therapeutics/alpha-synuclein-aggregation-inhibitors)
• [Prasinezumab](/therapeutics/prasinezumab)
• [Multiple System Atrophy](/diseases/multiple-system-atrophy)
• [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies)
• [Synucleinopathies](/mechanisms/synucleinopathies)

External Links

• [Vivace Therapeutics](https://www.vivacetx.com)
• [ClinicalTrials.gov: Buntanetap](https://clinicaltrials.gov)
• [Michael J. Fox Foundation - Alpha-Synuclein Research](https://www.michaeljfox.org)
• [Parkinson's Foundation - Research](https://www.parkinson.org)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Smartphone-Detected Motor Variability Correction](/hypothesis/h-072b2f5d) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: DRD2/SNCA
• [Microbial Metabolite-Mediated α-Synuclein Disaggregation](/hypothesis/h-74777459) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: SNCA, HSPA1A, DNMT1
• [Enteric Nervous System Prion-Like Propagation Blockade](/hypothesis/h-2e7eb2ea) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TLR4, SNCA

Related Analyses:

• [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;
• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;